PBS updates

Imfinzi (Durvalumab)

durvalumab 120 mg/2.4 mL injection, 2.4 mL vial · INJECTION · PBS code 15091G

STREAMLINED

What it costs

AU$860.99 PBS-determined price per pack

Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.

  • • First listed on the PBS: 2025-11-01.
  • • Repeats: 5.
  • • PBS program: IP.
Eligibility criteria for subsidised access

The following is the government's own wording from the PBS Schedule, shown unchanged.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Advanced (unresectable) Barcelona Clinic Liver Cancer Stage B or Stage C hepatocellular carcinoma


Initial treatment


Patient must be undergoing combination treatment with tremelimumab for the first dose of treatment; AND

Patient must have a WHO performance status of 0 or 1; AND

Patient must not be suitable for transarterial chemoembolisation; AND

Patient must have Child Pugh class A; AND

The condition must be untreated with systemic therapy; or

Patient must have developed intolerance of a severity necessitating permanent treatment withdrawal, in the absence of disease progression to a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI).

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Advanced (unresectable) Barcelona Clinic Liver Cancer Stage B or Stage C hepatocellular carcinoma


Continuing treatment


Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND

Patient must not have developed disease progression while being treated with this drug for this condition.

Sponsor: AstraZeneca Pty Ltd ABN 54 009 682 311

Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.